FierceBiotechOriginal article
{"a":[{"_":"Novartis secures new radioligand in $900M deal as competition strengthens","$":{"href":"/biotech/novartis-secures-new-radioligand-900m-deal-competition-strengthens","hreflang":"en"}}]}
PartnershipRadioligand therapyPositive
AI Analysis
Summary
Novartis has licensed a preclinical radioligand therapy from a Chinese biotech in a $900M deal to strengthen its radiopharmaceutical pipeline amid increasing competition in the sector.
Importance:7/10
Sentiment:
0.60
radioligand therapyradiopharmaceuticalslicensing dealpipeline expansiononcology
Related Companies
Read the original article
Published by FierceBiotech on September 22, 2026 1:26 PM
